General Information of Drug (ID: DMY60MG)

Drug Name
L-735,821 Drug Info
Synonyms
CHEMBL332826; AC1NQZS7; C13853; CHEBI:34807; L 735821; (E)-3-(2,4-dichlorophenyl)-N-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]prop-2-enamide; SureCN8611879; SCHEMBL8837547; SCHEMBL8611879; GTPL2592; CHEBI:303776; BDBM50061218; L735821; N-[[(3R)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin]-3-yl]-2,4-dichlorobenzeneacrylamide; 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acrylamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5282279
ChEBI ID
CHEBI:34807
TTD Drug ID
DMY60MG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indapamide DMGN1PW Edema MG29 Approved [3]
L-768673 DMZ402C N. A. N. A. Terminated [4]
zinc pyrithione DMF0CRA Discovery agent N.A. Investigative [5]
XE991 DMLH1PK Discovery agent N.A. Investigative [6]
N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide DM6EJQ4 Discovery agent N.A. Investigative [7]
(3R,4S)-293B DM47BEG Discovery agent N.A. Investigative [8]
HMR-1556 DMXMTA9 Discovery agent N.A. Investigative [9]
R-L3 DMGEDQJ Discovery agent N.A. Investigative [10]
3S,4R-293B DMVGDSM Discovery agent N.A. Investigative [8]
N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide DMEUXOQ Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv7.1 (KCNQ1) TT846HF KCNQ1_HUMAN Blocker [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2592).
2 Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol. 2003 Jul;64(1):70-7.
3 Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84.
4 Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(... J Med Chem. 1997 Nov 21;40(24):3865-8.
5 Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
6 Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23.
7 Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
8 A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54.
9 Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14.
10 A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 1998 Jul;54(1):220-30.